3D Model of lymphoma

Applications

First DLBCL (Diffuse Large B-cell Lymphoma) 3D model for high-throughput drug screening and personalized medicine.

• Drug discovery for DLBCL treatment
• Pre-clinical tests for response to treatment and patients orientation

1. Increase success rate of new molecules in clinical phases
2. Huge economic potential

Challenges

Therapeutic failures are due to the absence of relevant models for testing new drugs and the lack of adequate testing to guide treatment for each patient individually.

• Need to identify new therapeutic targets: 40-50% of patients are resistant or relapse
• Need to develop new study models:
  • conventional suspension culture of primary tumor cells of patients fail because non-Hodgkin lymphomas are dependent on the microenvironment
  • xenografts in mice have limitations: expensive, not very reproducible, can not be used large scale, do not mimic the microenvironment tumor

Competitive advantages of our solution

• Mimesis of the niche of lymphatic ganglion: architecture, bio-mechanical constraints, microenvironment of lymphoma
• Large-scale production and reproducibility : 5000 capsules per second of uniform size
• Ease of manipulation and transport: possibility of recovering cells spheroids for analysis

Benefits

• Spheroids models have a more faithful response to chemotherapy
• Good yield compatible with high-throughput screening
• Low cost of production, process compatible with industrial requirements